Skip to content

Discontinued — last reported Q4 '25

Operating Expenses

Impairment Charges

This increase may warrant attention — for this metric, lower values are generally preferred.

Analysis

StatementIncome Statement
SectionOperating Expenses
CategoryRisk
SignalLower is better
VolatilityVolatile
First reportedQ1 2013
Last reportedQ4 2025Feb 13, 2026

How to read this metric

An increase signals potential issues with asset quality, failed projects, or overly optimistic past valuations.

Detailed definition

Impairment charges represent the write-down of the carrying value of non-goodwill assets when their fair value falls bel...

Peer comparison

Standard accounting adjustment; high frequency or magnitude often triggers investor scrutiny regarding management's capital allocation.

Metric ID: impairment_charges

Historical Data

12 periods
 Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Value$0$0$0$0$0$0$0$0$379M$0$0$0
QoQ Change-100.0%
Range$0$379M

Business Segments

View all
SegmentQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Pharmaceuticals$379M$0$0$0$0
Total$379M$0$0$0

Impairment Charges at Other Companies

Frequently Asked Questions

What is Vertex Pharmaceuticals's impairment charges?
Vertex Pharmaceuticals (VRTX) reported impairment charges of $0 in Q4 2025.
What does impairment charges mean?
A non-cash expense recorded when an asset's value drops significantly below its recorded book value.